BioSpace News Archive

Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces today that Chief Executive Officer Tom Hallam, Ph.D. will present at the H.C. Wainwright Global Investment Conference.

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the Phase 1b/2 study of sabizabulin (VERU-111)

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it has completed the acquisition of U.S. and Canadian rights to ELYXYB™ (celecoxib oral solution) from Dr. Reddy’s Laboratories Limited.

The American Urological Association and the Sexual Medicine Society of North America will be releasing a new clinical practice guideline to aid in the diagnosis, evaluation and treatment of acute ischemic priapism in men.

CSL’s Global Chief Human Resources Officer Elizabeth Walker has been appointed to the Urban League of Philadelphia’s Board of Directors.

Natera, Inc. today announced the launch of Prospera with Quantification, the only cfDNA test for kidney rejection that provides three values

Galderma to Present New Data From Leading Aesthetics Portfolio and Launch * RESTYLANE ® EYELIGHT™ at AMWC 2021

Appointments represent Jaguar’s focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization of crofelemer prescription product for chemotherapy-induced diarrhea in dogs. Company to host investor webcast Monday, September 20th at 8:30 a.m. Eastern;

Altamira Therapeutics Ltd. today announced that its Chairman and CEO, Thomas Meyer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, to be held virtually September 13-15, 2021.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce its participation in the H.C. Wainwright 23rd Annual Global Investment Conference (“the Conference”), taking place virtually on September 13-15, 2021.